inHEART, a medical device company offering an advanced and AI-driven digital twin of the heart announced it has raised $11 million to drive commercial growth of its therapeutic software solution for cardiac ablation procedures and advance the development of its predictive cardiac models for heart failure, sudden cardiac death, and cardio-embolic stroke.
This funding was led by Vesalius Biocapital IV and co-led by Elaia Partners with participation from NACO, Sagana, Sofia Angel Ventures, CWR Funds, and Webit Investment Network. And inHEART received funds from a successful crowd equity campaign on Tudigo and the UK impact fund Astorg Foundation.
inHEART’s current therapeutic solution handles the challenges of conventional cardiac ablations. The solution creates highly detailed, interactive 3D heart models with proprietary AI-driven cardiac CT or MR image segmentation. These 3D heart models enable physicians to optimize treatment strategies based on each patient’s unique cardiac anatomy and support pre-procedural planning for faster ablation procedures and improved clinical outcomes.
The funding from this round will also support the development of new product verticals for AI-driven predictive software models for sudden cardiac death and cardio-embolic stroke, as well as a new therapeutic software solution to help physicians treat heart failure patients. And currently, inHEART is commercially available in the US and EU through a direct sales force model, with plans to establish a global distribution network in the coming months to further accelerate growth.
KEY QUOTES:
“We welcome this strong international group of investors to our latest round of financing. This new round allows us to go further in addressing the needs of cardiac patients from early screening and disease detection through advanced therapeutic support. It’s exciting for us to be at the forefront of transforming the healthcare industry with the power of AI technology by improving the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions.”
– Todor Jeliaskov, Chairman and CEO of inHEART
“We are enthusiastic to continue our support and co-lead this financing round for inHEART. inHEART’s AI-driven 3D cardiac mapping enables unprecedented precision in targeting and treating arrhythmias, setting new standards in the treatment of heart conditions.”
– Samantha Jérusalmy, board member at inHEART and Partner at Elaia
“At Vesalius Biocapital IV, we’re dedicated to supporting advancements in medical technology that improve patient care. inHEART’s AI-driven solutions exemplify the future of cardiac care, offering personalized therapy options and predictive models that can enhance clinical outcomes and streamline treatment processes. We’re excited to contribute to inHEART’s journey as they revolutionize cardiac care and address global healthcare needs with cutting-edge technology and innovation.”
– Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital IV
